View Financial HealthSCHOTT Pharma KGaA 配当と自社株買い配当金 基準チェック /26SCHOTT Pharma KGaA配当を支払う会社であり、現在の利回りは0.99%で、収益によって十分にカバーされています。主要情報1.0%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回り1.1%配当成長10.3%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向19%最近の配当と自社株買いの更新お知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.すべての更新を表示Recent updatesReported Earnings • May 14Second quarter 2026 earnings released: EPS: €0.21 (vs €0.25 in 2Q 2025)Second quarter 2026 results: EPS: €0.21 (down from €0.25 in 2Q 2025). Revenue: €247.9m (down 1.5% from 2Q 2025). Net income: €31.0m (down 19% from 2Q 2025). Profit margin: 13% (down from 15% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.お知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.New Risk • Jan 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.お知らせ • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.Reported Earnings • Dec 14Full year 2025 earnings released: EPS: €0.97 (vs €0.99 in FY 2024)Full year 2025 results: EPS: €0.97 (down from €0.99 in FY 2024). Revenue: €986.2m (up 3.0% from FY 2024). Net income: €146.5m (down 2.2% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe.お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €15.10, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €29.64 per share.New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025お知らせ • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026お知らせ • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026お知らせ • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.お知らせ • Nov 16SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 10, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results on Dec 10, 2025決済の安定と成長配当データの取得安定した配当: 配当金の支払いは安定していますが、 1SXPが配当金を支払っている期間は 10 年未満です。増加する配当: 1SXPの配当金は増加していますが、同社は2年間しか配当金を支払っていません。配当利回り対市場SCHOTT Pharma KGaA 配当利回り対市場1SXP 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (1SXP)1.0%市場下位25% (IT)1.6%市場トップ25% (IT)4.7%業界平均 (Life Sciences)0.8%アナリスト予想 (1SXP) (最長3年)1.1%注目すべき配当: 1SXPの配当金 ( 0.99% ) はItalian市場の配当金支払者の下位 25% ( 1.57% ) と比べると目立ったものではありません。高配当: 1SXPの配当金 ( 0.99% ) はItalian市場の配当金支払者の上位 25% ( 4.67% ) と比較すると低いです。株主への利益配当収益カバレッジ: 1SXPは低い 配当性向 ( 18.9% ) であるため、配当金の支払いは利益によって十分にカバーされます。株主配当金キャッシュフローカバレッジ: 1SXPの 現金配当性向 ( 46.3% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YIT 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 23:07終値2026/05/29 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SCHOTT Pharma AG & Co. KGaA 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23 アナリスト機関Gaurav JainBarclaysPallav MittalBarclaysJonathon UnwinBarclays20 その他のアナリストを表示
お知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.
お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.
Reported Earnings • May 14Second quarter 2026 earnings released: EPS: €0.21 (vs €0.25 in 2Q 2025)Second quarter 2026 results: EPS: €0.21 (down from €0.25 in 2Q 2025). Revenue: €247.9m (down 1.5% from 2Q 2025). Net income: €31.0m (down 19% from 2Q 2025). Profit margin: 13% (down from 15% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
お知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.
New Risk • Jan 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
お知らせ • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.
Reported Earnings • Dec 14Full year 2025 earnings released: EPS: €0.97 (vs €0.99 in FY 2024)Full year 2025 results: EPS: €0.97 (down from €0.99 in FY 2024). Revenue: €986.2m (up 3.0% from FY 2024). Net income: €146.5m (down 2.2% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe.
お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €15.10, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €29.64 per share.
New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025
お知らせ • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026
お知らせ • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026
お知らせ • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.
お知らせ • Nov 16SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 10, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results on Dec 10, 2025